Prostate-specific antigen after radiation therapy: Prognosis by pretreatment level and post-treatment nadir

Urologic Clinics of North America

Volumn 24, Issue 2, 1997, Pages 407-414

  Schellhammer, P F ^a   El Mahdi, A M ^a   Kuban, D A ^a   Wright G L , Jr ^a  

^a Sentara Cancer Resource Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; ORAL DRUG ADMINISTRATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE; TUMOR VOLUME;

EID: 0030992364     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70387-6     Document Type: Article

References (42)

1. J. Adolfsson B. Tribukait Evaluation of tumor progression by repeated fine needle biopsies in prostate adenocarcinoma: Modal deoxyribonucleic acid value and cytological differentiation J Urol 144 1990 1408 1420
2. M.A. Bagshaw R.S. Cox S.L. Hancock Control of prostate cancer with radiotherapy: Long-term results J Urol 152 1994 1781 1784
3. Blasko J: Prostate Cancer: Horizons in Transperineal Therapy. Fifth Annual Symposium. Seattle, Washington, 1994.
4. P.N. Brawn The dedifferentiation of prostate carcinoma Cancer 52 1983 246 251
5. F. Critz K. Levinson H. Williams What PSA nadir level should be achieved after irradiation for prostate cancer? May 1996 American Society of Clinical Oncology presentation Philadelphia
6. F.A. Critz R.S. Tarlton D.A. Holladay Prostate specific antigen monitored combination radiotherapy for patients with prostate cancer Cancer 75 1995 2383 2391
7. E.P. Diamandis H. Yu New biological functions of prostate-specific antigen [editorial]? J Clin Endocrinol Metab 80 1995 1515
8. J. Fijuth B. Chauvet P. Vincent Serum prostatic-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy Radiother Oncol 23 1992 236 240
9. R.W. Geist Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate Urology 45 1995 1016
10. B.M. Grob P.F. Schellhammer D. Brassil Changes in immunohistochemical staining of PSA, PAP and TURP-27 following irradiation therapy for clinically localized prostate cancer Urology 44 1994 525
11. G.E. Hanks J.M. Krall A.L. Hanlon Patterns of care and RTOG studies in prostate cancer: Long-term survival, hazard rate observations, and possibilities of cure Int J Radiat Oncol Biol Phys 28 1994 39 45
12. G.E. Hanks W.R. Lee A.L. Hanlon Conformal technique dose escalation in prostate cancer: Improved cancer control with higher doses in patients with pretreatment PSA > 10 ng/mL [abstract 2] Int J Radiat Oncol Biol Phys 32 1995 141
13. G. Hanks C. Perez M. Kozar PSA confirmation of cure at 10 years of T1b, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation Int J Radiat Oncol Biol Phys 30 1994 289
14. I.D. Kaplan R.S. Cox M.A. Bagshaw Prostate specific antigen after external beam radiotherapy for prostatic cancer: Followup J Urol 149 1993 519 522
15. V. Kavadi G. Zagars A. Pollack Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications Int J Radiat Oncol Biol Phys 30 1994 270
16. D. Kuban A. El-Mahdi P. Schellhammer Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer Int J Radiat Oncol Biol Phys 32 1995 307
17. P. Kupelian H. Levin C. Zippe A contemporary series of external beam radiotherapy versus radical prostatectomy for localized prostate cancer: A single institution experience [abstract 982]. A single institution experience [abstract 982] J Urol 155 suppl 1996 556A
18. W.R. Lee G.E. Hanks T.E. Schultheiss Localized prostate cancer treated by external beam radiotherapy alone: Serum prostate-specific antigen: Driven outcome and analysis J Clin Oncol 13 1995 464
19. Leibman BD, Dillioglugil O, Rogers E, et al: Analyzing PSA trends in recurrent patients after radical prostatectomy (RP) and radiotherapy (XRT): A novel analysis [abstract 1550]. Proceedings of American Urologic Association, vol. 155, April 1996
20. A. Malcolm M.D. Bagshaw H.S. Kaplan Comments on the treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome—IJROBP 32:287–292, 1995 Int J Radiat Oncol Biol Phys 32 1995 541 543
21. C. Mettlin G.W. Jones G.P. Murphy Trends in prostate cancer care in the United States, 1974–1990: Observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer CA Cancer J Clin 43 1993 83
22. J.E. Oesterling D.W. Chan J.L. Epstein Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radial prostatectomy J Urol 139 1988 766
23. A.W. Partin C.R. Pound J.Q. Clemens Serum PSA after anatomic radical prostatectomy Urol Clin North Am 20 1993 713
24. C.A. Perez Carcinoma of the prostate: A model for management under impending health care system reform Radiology 196 1995 309 322
25. T.M. Pisansky S.S. Cha J.D. Earle Prostate-specific antigen as a pre-therapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer J Clin Oncol 11 1993 2158 2166
26. N.J. Prendergast M.R. Atkins E.C. Schatte p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma J Urol 155 1996 1685 1692
27. 4Urology UCSF/MTZ J Urol 156 1996 1719 1723
28. K.J. Russell R.G. Caplan G.E. Laramore Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: Preliminary results of a randomized prospective trial of the Neutron Therapy Collaborative Working Group Int J Radiat Oncol Biol Phys 28 1994 47 54
29. K.J. Russell G.E. Laramore J.M. Krall Eight years experience with neutron radiotherapy in the treatment of stages C and D prostate cancer: Updated results of the RTOG 7704 randomized clinical trial Prostate 11 1987 183 193
30. H.M. Sandler W. McLaughlin K.E. Kish Results of 3D conformal radiotherapy in the treatment of 707 patients with localized prostate cancer [abstract 1] Int J Radiat Oncol Biol Phys 32 1995 141
31. P.F. Schellhammer A.M. El-Mahdi G.L. Wright Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate Urology 42 1993 13 20
32. Schellhammer P, Cockett A, Buccon-Gibod L, et al: Assessment of endpoints for clinical trials for localized prostate cancer. Urology (suppl), in press
33. W.U. Shipley L.J. Verhey J.E. Munzenrider Advanced prostate cancer: The results of a randomized comparative trial of high dose irradidation boosting with conformal protons compared with conventional dose irradiation using photons alone Int J Radiat Oncol Biol Phys 32 1995 3 12
34. T.A. Stamey M.K. Ferrari H.P. Schmid The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steeply increasing values characterize 80% of patients [letter] J Urol 152 1994 492 495
35. T.A. Stamey N. Yang A.R. Hay Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909
36. M. Tibbs A. Zeitman K.C. Dallow Biochemical outcome following external beam radiation for T1-2 prostate carcinoma: The importance of achieving an undetectable nadir PSA Int J Radiat Oncol Biol Phys 32 suppl 1 1995 230
37. S. Vijayakumar S.F. Quadri S. Sen Measurement of weekly prostate specific antigen levels in patients receiving pelvic radiotherapy for nonprostatic malignancies Int J Radiat Oncol Biol Phys 32 1995 189 195
38. J.A. Wheeler G.K. Zagars A.G. Ayala Dedifferentiation of locally recurrent prostate cancer after radiation therapy: Evidence for tumor progression Cancer 71 1993 3783 3787
39. C.G. Willett A.L. Zietman W.U. Shipley The effect of pelvic radiation therapy on serum levels of prostate specific antigen J Urol 151 1994 1579 1581
40. G. Zagars Serum PSA as a tumor marker for patients undergoing definitive radiation therapy Urol Clin North Am 20 1993 737
41. G.K. Zagars A. Pollack The fall and rise of prostate-specific antigen: Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer Cancer 72 1993 832 842
42. A.L. Zietman J.J. Coen W.U. Shipley Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate-specific antigen value as a predictor of treatment outcome J Urol 151 1994 640 645